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Abstract
Research on pediatric Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is reviewed 
in this article. Many recent articles in this area highlight the existence of key differences between the 
adult and pediatric forms of the illness. This review article provides an overview of pediatric ME/
CFS, including epidemiology, diagnostic criteria, treatment, and prognosis. Challenges to the field 
are identified with the hope that in the future pediatric cases of ME/CFS can be more accurately 
diagnosed and successfully managed.
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Pediatric Myalgic Encephalomyelitis/
Chronic Fatigue Syndrome
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a protracted and persistent illness 
that produces a variety of debilitating effects in children and adolescents [1,2]. While a hallmark sym-
ptom of ME/CFS is profound fatigue, sufferers report a wide variety of concomitant symptoms inclu-
ding post-exertional malaise, body, myofascial and/or joint pain, cognitive difficulties, unrefreshing or 
disturbed sleep, headaches, and sore throat. Some symptoms are more common than others; however, 
the condition is characterized by unique symptom patterns and unpredictable symptom severity, which 
further complicates both treatment and prognosis [3].
Children and adolescents often present with symptoms that differ from their adult counterparts [4]. 
For example, stomachaches and rash are often reported in cases of pediatric ME/CFS, but are far less 
common in adults [2,3]. According to Bell [5], the three most common symptoms (aside from fatigue) 
in children with ME/CFS were headaches, sleep disturbance, and cognitive difficulties. Furthermore, 
children and adolescents may exhibit symptoms in response to their unique day-to-day routine (i.e., 
trouble in school, loss of friends, dropping out of extracurricular activities, etc.), and, due to their still-
developing coping skills, are more apt to display irritability in response to the disease [2].
Dowsett and Colby [6] found ME/CFS to be the most common cause of prolonged medical leave from 
school among adolescents. In another study, Carter and colleagues [7] found that 55% of children with 
ME/CFS reported a decline in academic performance since illness onset and 80% indicated major 
reduction in extracurricular activities. Smith and colleagues [8] found that one third of adolescents 
with ME/CFS report severe restrictions of all activities and marked drops in school performance; some 
missed up to 80 days in a six-month period.
Epidemiology
Epidemiologic methods summarize information about the distribution of illnesses and allow investi-
gators to make inferences about the importance of risk factors or even causal factors (e.g., smoking 
as a precursor to cancer). However, even if the specific cause of an illness or social condition is not 
known, epidemiologists can uncover associations between risk factors that can lead to important ways 
of understanding the etiology and maintenance of an illness [9]. If biased sampling methods such as 
the utilization of physician gatekeepers to identify cases of myalgic encephalomyelitis/chronic fatigue 
syndrome (ME/CFS) result in an over- or underestimate of the true prevalence rate, it may impede 
efforts to understand the nature of the condition. This error occurred with the first generation of adult 
ME/CFS prevalence studies. Reyes and colleagues[10] published epidemiologic research that portra-
yed ME/CFS as being relatively rare, affecting about 20,000 adults, and characterized patients as being 
European-American and middle to upper-class women. These findings supported the myth of ME/CFS 
as a “YUPPIE flu” disease. So as long as scientists and the public perceived ME/CFS as rare, those with 
this illness would be unlikely to receive the needed federal attention and community resources to de-
velop a better understanding of this illness. This CDC epidemiologic study was based on a method that 
relied on physician referral of patients with ME/CFS [10]. However, if the physicians did not believe the 
illness existed, or if patients did not have a physician, many people with ME/CFS would not be referred 
to researchers or counted in prevalence surveys.
A second generation of adult prevalence studies involved a randomly selected group of individuals 
being telephoned and screened for symptoms of ME/CFS [11]. Those who were identified in the te-
lephone screen as having several ME/CFS symptoms underwent a complete medical and psychiatric 
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examination to determine whether they actually had ME/CFS. This study estimated that over 800,000 
people had ME/CFS, and this illness was found to be more prevalent among people of color. This study 
[11] and others [12] that used community-based samples differed from the methods used in the earlier 
CDC study [10] whereby physicians determined who was referred as a possible ME/CFS case.
Pediatric epidemiology
ME/CFS, involving 6 or more months of fatigue and other symptoms [1,13,14], causes significant im-
pairment to various aspects of children’s and adolescents’ lives including physical functioning, school 
attendance and performance, and extracurricular activities [15]. Krilov and colleagues [16] found that 
only 14% of adolescents with ME/CFS attended school regularly after onset. Dowsett and Colby [17] 
found ME/CFS to be the most common cause of prolonged medical leave from school among adole-
scents, and yet there are no rigorous pediatric community-based ME/CFS prevalence estimates. In a 
25-year follow up of a sample of pediatric patients with ME/CFS, Brown, Bell, Jason, and Christos [18] 
found that those patients that had improved still showed significantly more impairment on 23 of the 25 
outcomes evaluated compared to a healthy control group. This study indicates that even though some 
youth with ME/CFS over time will not meet diagnostic criteria for ME/CFS, they remain symptomatic 
and may not return to their premorbid level of functioning.
The prevalence of pediatric ME/CFS has been under dispute. No rigorous community-based epidemio-
logic study has been conducted in in the US or internationally. Accurate sampling and measurement 
have been at the heart of the debate among researchers. If medical personnel believe that pediatric ME/
CFS is a relatively rare disorder, then physicians might minimize or misinterpret the physical com-
plaints of ME/CFS patients, leading to the mistrust and lack of communication that has been reported 
between patients and medical personnel. In the US, the CDC conducted a surveillance study [19] and 
estimated that, among adolescents aged 12-17, 2.7 per 100,000 had ME/CFS, indicating that ME/CFS 
was a relatively rare disorder among youth. A major limitation of this study and a comparable study in 
Australia [20] was that the samples were obtained through physician referral; therefore, members of 
the community that do not or cannot access medical care for their symptoms were not included. The 
CDC conducted another study involving referrals from school nurses from middle and high schools 
in Wichita, Kansas, and Reno, Nevada. An ME/CFS prevalence of 24.0 per 100,000 was found for the 
12 to 17 year old age group [21]. As in other medical referral studies, the gatekeeper methodology, as 
well as reliance on previous diagnoses by physicians (rather than current evaluations), limited the va-
lidity of these findings. Another CDC study involved a community-based investigation conducted in 
San Francisco [21]. This study employed random digit dialing to households as a means of identifying 
children and adolescents with ME/CFS-like illness. In adolescents aged 12-17, 116.4 per 100,000 were 
diagnosed with ME/CFS-like conditions. Unfortunately, these self-reports were not confirmed with 
medical assessments. A final CDC prevalence study by Jones and colleagues [22] involved a random 
digit dialing survey of the residents of Wichita, Kansas. The prevalence of pediatric ME/CFS-like illness 
was 338 per 100,000. Because this study did not include a medical evaluation of the pediatric sample, 
the actual number of ME/CFS cases in that population could not be determined; only “ME/CFS-like” 
illness could be diagnosed. The same problem pertains to recent pediatric estimates generated in the 
Netherlands [23]. To date, existing studies of ME/CFS in youth have lacked the ability to rigorously 
estimate the overall prevalence of pediatric ME/CFS or examine risk factors for the illness.
Diagnostics
The Fukuda et al. criteria [13] identify cases of ME/CFS for an adult population and may not be appro-
priate to diagnose and identify children with this illness. Children experience different ME/CFS sym-
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ptomatology than adults, for example, more frequently reporting abdominal pain and rashes [24]. Fur-
thermore, youth with ME/CFS may experience more day to day fluctuations in their symptom severity 
[25]. In 2006, the International Association of Chronic Fatigue Syndrome (IACFSME) developed a Pe-
diatric ME/CFS case definition [1]. The pediatric ME/CFS case definition requires more specification 
of critical symptoms [1] than the Fukuda et al. criteria [6]. The symptom categories included fatigue, 
post-exertional malaise, unrefreshing sleep or disturbance of sleep quantity, pain (myofascial, joint, 
abdominal and/or head pain), two or more neurocognitive manifestations, and at least one symptom 
from two of the following three categories: autonomic manifestations, neuroendocrine manifestations, 
or immune manifestations.
In addition, to meet this pediatric ME/CFS case definition [1], the children must have the concurrent 
occurrence of the following classic ME/CFS symptoms, which must have persisted or recurred during 
the past three months of illness (symptoms may predate the reported onset of fatigue). Support for the 
inclusion of these symptoms emerged from Rowe and Rowe’s [26] confirmatory factor analysis, which 
found muscle pain and fatigue, neurocognitive, abdominal, head and chest pain, neurophysiological, 
and immunological factors. We recommend using the Pediatric ME/CFS Questionnaire, which provi-
des a way of gathering this information to help diagnose pediatric ME/CFS [1]. It is generally recom-
mended that adolescents age 12 and older fill it out themselves, and parents can assist or fill it out for 
the children 11 and under. Some children might need to complete the questionnaire over several days if 
completion exacerbates the children’s symptoms. It is important to rate each symptom for severity and 
frequency, and to operationalize criteria to meet the case definition. Using the question: “how much 
does this symptom bother you,” for a symptom to meet criteria, it should be rated a 4 or higher on the 
following scale: 1 = no problem, 4 = moderate problem, 7 = big problem. In regards to how often the 
child has the symptom, to meet criteria, a symptom would have to be rated a 4 or higher on the fol-
lowing scale: 1 = hardly ever, to 4= half of the time, to 7 = always.
Post-exertional malaise and/or post-exertional fatigue
With activity (it need not be strenuous and may include walking up a flight of stairs, or as minimal as 
using a computer or reading a book), there must be a loss of physical or mental stamina, rapid/sudden 
muscle or cognitive fatigability, post-exertional malaise and/or fatigue and a tendency for other asso-
ciated symptoms within the patient’s cluster of symptoms to worsen. The recovery is slow, often taking 
24 hours or longer.
Unrefreshing sleep or disturbance of sleep quantity or rhythm disturbance
These symptoms may include prolonged sleep (including frequent naps), disturbed sleep (e.g., inability 
to fall asleep or early awakening), and/or day/night reversal.
Pain (or discomfort)
These symptoms are often widespread and migratory in nature. There needs to be the occurrence of 
at least one symptom from the following: myofascial and/or joint pain, abdominal and/or head pain. 
Myofascial pain can include deep pain, muscle twitches, or achy and sore muscles. Pain, stiffness, or 
tenderness may occur in any joint but must be present in more than one joint without signs of in-
flammation. Children with abdominal and/or head pain may experience eye pain/sensitivity to bright 
light, stomach pain, nausea, vomiting, or chest pain. People with ME/CFS often describe headaches as 
localized behind the eyes or in the back of the head, and may include headaches localized elsewhere, 
including migraines.
Children must also experience two or more neurocognitive manifestations which can include: impai-
red memory (self-reported or observable disturbance in ability to recall information or events on a 
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short-term basis), difficulty focusing (disturbed concentration may impair ability to remain on task, to 
screen out extraneous/excessive stimuli in a classroom, or to focus on reading, computer/work activity, 
or television programs), difficulty finding the right word, frequently forgetting what one wanted to say, 
absent mindedness, slowness of thought, difficulty recalling information, needing to focus on one thing 
at a time, trouble expressing thought, difficulty comprehending information, frequently losing train of 
thought, or experiencing new trouble with math or other subjects.
Finally, the child must experience at least one symptom from two of the following three categories:
 • Autonomic manifestations: neurally mediated hypotension, postural orthostatic tachycardia, de-
layed postural hypotension, palpitations with or without cardiac arrhythmias, dizziness, feeling 
unsteady on the feet with disturbed balance and/or shortness of breath.
 • Neuroendocrine manifestations: recurrent feelings of feverishness and cold extremities, subnormal 
body temperature and marked diurnal fluctuations, sweating episodes, intolerance of extremes of 
heat and cold, marked weight change, loss of appetite or abnormal appetite, worsening of symptoms 
with stress.
 • Immune manifestations: recurrent flu-like symptoms, non-exudative sore or scratchy throat, repe-
ated fevers and sweats, lymph nodes tender to palpitation--generally minimal swelling noted, new 
sensitivities to food, odors, or chemicals.
Severe versus moderate categories
We created a separate category for those who did not meet full criteria but were still symptomatic, and 
they were classified as Moderate ME/CFS Clinical. These adolescents need to have 3 or more months of 
fatigue and need to report four out of the five classic ME/CFS symptoms with frequency and severity 
ratings of moderate or severe (a rating of 4 or higher, on a scale of 1-7). In addition, for autonomic, 
neuroendocrine, and immune manifestations, adolescents need at least one symptom in any of these 
three categories, as opposed to one symptom from two of the three categories.
Other categories
The pediatric case definition for ME/CFS also diagnoses children and adolescents with subtype varia-
tions of ME/CFS for those who experience idiopathic chronic fatigue. One subtype is atypical ME/CFS, 
which is defined as 3 or more months of fatigue, but missing more than one classic ME/CFS symptom. 
It is also possible to receive a diagnosis of ME/CFS in remission, if they met full symptom criteria at 
one time but were not experiencing full symptomatology at the time of the study. Another category is 
pediatric ME/CFS-like illness, which is defined as meeting all classic ME/CFS symptom criteria, except 
for the 3 month duration. This diagnosis (ME/CFS-like) could also be given to a child or adolescent 
who has not undergone a medical evaluation.
The IACFSME working group created a new assessment tool, the DePaul Pediatric Health Question-
naire (DPHQ), which is a self-report measure of ME/CFS symptoms for children who are under the age 
of 18 years old. Several theorists recommended that the ME/CFS diagnostic process would be impro-
ved with the inclusion of symptom severity ratings because of the disparities in symptoms often found 
among patients with ME/CFS [27,28]. Consequently, the DPHQ measures the presence or absence 
of symptoms, and also the severity and frequency of the symptoms in six specific symptom domains. 
Thus, the DPHQ captures a more accurate assessment of pediatric ME/CFS symptoms and accounts for 
the heterogeneous nature of this illness.
A study by Jason and colleagues [1] compared the new diagnostic criteria for Pediatric ME/CFS [1] 
with the Fukuda et al. [6] criteria in a sample of adolescent patients with ME/CFS and controls. Physi-
cians referred thirty-three children and adolescents as having pediatric ME/CFS and twenty-one he-
althy children and adolescents. The Fukuda et al. criteria were less sensitive than the Pediatric ME/
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CFS criteria in identifying pediatric ME/CFS cases. Findings suggest the Fukuda et al. criteria are less 
effective than the Pediatric ME/CFS criteria in correctly diagnosing cases of pediatric ME/CFS.
In another study [29], using the same sample as Jason and colleagues [1], physicians specializing in 
pediatric ME/CFS referred thirty-three pediatric patients with ME/CFS and twenty-one youth without 
the illness. Those who met ME/CFS criteria were separated into severe and moderate categories. Si-
gnificant differences were found for symptoms within each of the six major categories: fatigue, post-
exertional malaise, sleep, pain, neurocognitive difficulties, and autonomic/neuroendocrine/immune 
manifestations. In general, the results showed that participants who met the severe ME/CFS criteria 
reported the highest scores, the moderate ME/CFS group scored lower than severe, and the control 
group evidenced the lowest scores. Findings indicate that the Pediatric Case Definition for ME/CFS 
can distinguish between those with this illness and controls, and between those with severe versus 
moderate manifestations of the illness.
Hypothalamic-Pituitary-Adrenal (HPA) Axis Dysfunction
Cortisol serves as the main signaling hormone of the HPA axis. Dysregulation of glucocorticoid fun-
ction is associated with ME/CFS [30-33]. Patients with ME/CFS have lower cortisol secretion [34], a 
pattern of glucocorticoid resistance [35], and a disruption or dysregulation of the expected diurnal 
cortisol pattern [36]. The presence of HPA axis dysregulation in adolescence may serve as a predictor 
of this illness [37]. For example, Miike and colleagues [38] found that cortisol secretion was reduced 
in a pediatric ME/CFS population in comparison to controls. In addition, prior adverse events can 
“prime” inflammatory responses, promoting excessive cytokine production in response to subsequent 
stressors [39]. Thus, prior life adversity may produce stable alterations in processes that regulate the 
inflammatory response to subsequent stress [40]. Attenuated decline of salivary cortisol concentra-
tions across the day and increased IL-6 concentration, a key mediator of such inflammatory responses, 
have been associated with fatigue symptoms in ME/CFS [41]. Others have found higher levels of pro-
inflammatory immune responses, including IL-8 [42] and TNF-alpha [43] for individuals with ME/
CFS versus controls.
Variance in the expression of genes associated with HPA axis function has been found to be associated 
with ME/CFS [44-46]. For example, Rajeevan and colleagues [47] found that those with certain cortisol 
regulatory mechanisms (i.e., a single nucleotide polymorphism in the glucocorticoid receptor (GR) 
gene) were at increased risk for ME/CFS. Others have also found differences in the expression of gluco-
corticoid receptor NR3C1 in individuals with ME/CFS as compared to controls [33]. This suggests that 
patients with ME/CFS may have decreased sensitivity to the effects of cortisol due to a down-regulation 
of this glucocorticoid receptor [35].
Those with ME/CFS demonstrated improvements in a clinical trial of hydrocortisone [48]. However, 
such therapies are not appropriate for long-term treatment due to adrenal suppression [49]. As other 
pharmacologic modalities have not been beneficial in providing consistent relief to those with ME/
CFS, it is important to investigate non-pharmacologic methods of influencing hormonal pathways.
Treatment
There have been several cognitive behavioral therapy (CBT) trials for children and adolescents with 
ME/CFS. In Great Britain, Chalder, Tong, and Deary [50] examined the effectiveness of CBT with fa-
milies of 11-18 year olds. Treatment consisted of family face-to-face treatment sessions every 2 weeks, 
for up to 15 sessions. Of the 23 enrolled patients, 15 were rated as improved at the six-month follow-
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up. Positive findings were also obtained for Viner and colleagues’ [51] outpatient multidisciplinary 
rehabilitative treatment involving graded activities, exercise programs, family sessions, and supportive 
care with 12-17 year-old adolescents with ME/CFS. In Australia, Denborough and colleagues [52] re-
ported benefits from a 4-week multidisciplinary inpatient treatment program for 39 adolescents with 
ME/CFS. Physical functioning scores improved significantly following treatment, and were maintai-
ned at 6 months. In another study, Wright and colleagues [53] compared two treatment programs 
for adolescents with ME/CFS. Those randomly assigned to the pacing program showed little impro-
vement in activity scores and deterioration in school attendance, whereas those provided a tailored, 
incremental rehabilitation program (emphasizing a gradual return to normal social activities and a 
gradual return to school) evidenced marked improvements in both activity and school attendance. 
Stulemeijer and colleagues [54] provided a randomized trial of cognitive behavior therapy to 10-17 
year old adolescents with ME/CFS. Of the 36 assigned to the CBT condition, 29 completed post-
assessment measures and 33 of 35 in the waiting list control condition completed the post-assessment. 
The patients were provided ten sessions over a five-month period. Patients in the treatment condition 
reported significantly greater decreases in both fatigue severity and functional impairment. Further, 
school attendance increased significantly more for those in the CBT condition. Patients sustained 
benefits from the intervention at 2-year follow-up [55]. Unfortunately, these studies have not incor-
porated biological markers.
Negative patient reactions to health care services and providers might in part be explained by the 
types of interventions offered to individuals with this illness. While CBT has been applied to many 
medical and psychiatric problems, from pain to fibromyalgia to depression, its application to ME/CFS 
has been more controversial. This might be due to several of the components of CBT as practiced by 
some European investigators (e.g. [56,57]). Typical of the psychogenic view of ME/CFS is a research 
group from the Netherlands [58] who believe that these individuals attribute their symptoms to physi-
cal causes, are overly preoccupied by their physical limitations, and do not maintain regular activity. 
According to this model, these factors cause individuals with ME/CFS to be functionally impaired, 
implying that the central problem with patients experiencing this condition is a psychosomatic pre-
occupation with one’s fatigue. Song and Jason [59] tested this model with individuals with ME/CFS, 
and found that it was not valid for those individuals. In addition, Price, Mitchell, Tidy, and Hunot 
[60] reviewed 15 studies of CBT with a total of 1,043 ME/CFS participants. At treatment’s end, 40% 
of people in the CBT group showed clinical improvement in contrast to only 26% in usual care, but 
changes were not maintained at a one- to seven-month follow-up when including people who had 
dropped out.
Patient reactions to CBT and graded exercise have been mixed. A survey of 2,338 ME and ME/CFS re-
spondents [61] found that 26% felt their condition worsened after trying CBT, and graded exercise was 
felt to be the treatment that negatively impacted the most people. Results of other surveys conducted by 
the ME Association showed that, of those that had received graded exercise therapy, 33.1% felt “much 
worse” and 23.4% judged themselves to be “slightly worse” [62]. Similarly, a survey of treated patients 
with ME/CFS found that 34% of those who tried graded exercise therapy perceived themselves to be 
worse [63].
The ability to employ an intervention that enables youth with ME/CFS to have more control over their 
environment may help normalize cortisol levels. There is evidence that this has occurred following a 
CBT intervention for adults with ME/CFS [64]. Unfortunately, in the Roberts et al. study [64], there 
was no control or comparison group, and only a pre- and post-intervention (CBT therapy) cortisol 
level test. Treatment studies in the ME/CFS area have rarely examined neuroendocrine and immune 
dysregulation. It is important to examine critical neuroendocrine pathways in adolescents with ME/
CFS at a time where other confounding conditions are minimized (e.g., long term use of multiple phar-
macologic interventions, other medical illnesses).
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Pacing has been a rehabilitation practice used to help patients with a number of painful somatic con-
ditions such as headaches [65]. Pacing has been defined as an approach that encourages patients to be 
as active as possible within the limits imposed by their illness [66,67]. While more minor symptoms 
are ignored, more serious symptoms such as onset of muscle weakness, dizziness, or a flu-like malaise 
indicate that their “limits” have been exceeded, and then patients can either rest or change to an acti-
vity involving different muscles [68]. Jason and colleagues [69] developed a randomized trial of non-
pharmacologic interventions for ME/CFS, including CBT and pacing. About 100 patients with ME/
CFS were randomly assigned to four interventions in which they were provided 13 biweekly sessions 
with a trained nurse therapist. Baseline, post-treatment, and six- and twelve-month follow-up data 
were collected. Although there were some differences among the four types of interventions, overall, 
individuals demonstrated general improvement across interventions. Jason, Benton, and colleagues 
[70] divided this sample into two groups of patients: those who were able to keep expended energy 
close to available energy and those who were not successful at this task. Those who were able to stay 
within their “energy envelope” had significant improvements in physical functioning and fatigue seve-
rity. Findings suggest that helping patients maintain appropriate energy expenditures in coordination 
with available energy reserves can help improve functioning over time.
Utilizing the same sample, Brown, Khorana, and Jason [71] found that those who were within their 
“energy envelope” before treatment showed more improvement in physical functioning and fatigue 
compared with those outside of their “energy envelope.” These findings suggest that an assessment of 
perceived available and expended energy could help guide the development of individualized, non-
pharmacologic interventions for people with ME/CFS.
Table I summarizes pediatric ME/CFS treatment studies.
Author, year [ref] Sample Design Treatment Results
Chalder et al., 
2002 [50]
11-18 year olds
(n = 23)
Uncontrolled Family CBT- 
bimonthly up to 
15 sessions
15/23 enrolled patients rated 
as improved on functioning and 
fatigue at 6-month follow-up
Denborough et 
al., 2003 [52]
13-19 year olds
(n = 35)
Uncontrolled Multidisciplinary 
inpatient tx: 4 weeks
Physical and emotional 
functioning improved following 
treatment, maintained at 6-month 
follow-up
Stulemeijer et al., 
2004 [54]
10-17 year olds
(n = 71)
RCT CBT: 10 sessions Tx group reported greater 
decreases in fatigue severity and 
functionality, greater increase in 
school attendance at 5-month 
follow-up
Viner et al., 
2004 [51]
9-17 year olds
(n = 48)
Non-randomized 
trial
Multidisciplinary 
outpatient program 
(graded activity, 
exercise programs, 
family sessions and 
supportive care) OR 
supportive care alone
Program group: higher wellness 
scores and school attendance 
compared to supportive care 
group; 43% of program group 
recovered compared to 4.5% of 
supportive care group
Wright et al., 
2005 [53]
11-19 year olds 
(n = 13)
Randomized 
feasibility study
Adaptive pacing 
OR incremental 
rehabilitation
Adaptive pacing: non-significant 
improvements. Rehabilitation 
group: marked improvements in 
activity and school attendance
Table I. Summary of pediatric ME/CFS treatment studies
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Prognosis
Given the lack of effective treatments available, the prognosis for children and adolescents with ME/
CFS tends to be poor [72]. While previous research suggests that young sufferers of ME/CFS have a 
better prognosis than their adult counterparts [75], a recent study disputes this idea. Brown and colle-
agues’ [72] research examined long-term health outcomes of 25 people who were diagnosed with ME/
CFS while they were adolescents, approximately 25 years ago. Researchers assessed whether partici-
pants maintained their ME/CFS diagnosis, as well as current levels of health and functioning. Of the 
25 participants diagnosed with ME/CFS 25 years ago, only five self-reported maintaining a diagnosis, 
while 20 reported remission from the disease. In spite of their self-reported remission, those 20 parti-
cipants showed significantly more impairment compared to controls, demonstrating that, while adole-
scents diagnosed with the disorder may show some improvements over time, they still suffer some level 
of impairment and may not return to their premorbid level of functioning.
Further support for Brown and colleagues’ [72] findings is seen in Joyce, Hotopf, and Wessely’s [74] 
review of longitudinal ME/CFS studies. They found that fewer than 10% of adult participants across 
studies reported returning to premorbid functioning. A more recent review found a median ME/CFS 
recovery rate of 5%, although there was variability in recovery rates across studies [73]. These findings 
highlight both the vastly debilitating nature of the disease, as well as the need for further longitudinal 
research in this area [72].
Discussion
Clearly, there is a need to examine the prevalence of pediatric ME/CFS in a community-based sample, 
as well as the relative frequency of ME/CFS among various groups (e.g., different age groups, genders, 
racial/ethnic groups, and socioeconomic strata) and to compare these samples to ones generated from 
community controls. Regrettably, because of the lack of community-based samples of pediatric ME/
CFS, it is not possible to describe basic characteristics of pediatric patients with this illness. Arav-Boger 
and Spirer [75] describe the usual pediatric patient as being previously athletic and ambitious, upper 
middle-class, and having close relatives with ME/CFS. In some ways, these findings resemble how 
adults with ME/CFS were described following the first generation of epidemiologic studies. Yet these 
data and other studies on youth with ME/CFS [76-78] may be misleading as they are based primarily 
upon patients seen in pediatric or adolescent clinics. Children and adolescents with ME/CFS may be 
misdiagnosed or undiagnosed, have limited access to healthcare, or have a physician who discounts 
their symptoms, and, thus, may not be included in such studies [79]. In addition, characteristics from 
adult ME/CFS samples might not apply to youth, as children may experience different symptoms than 
adults with ME/CFS [77]. Symptoms such as rashes, abdominal pain, and orthostatic intolerance (OI) 
symptoms may be frequently present in pediatric ME/CFS but are not as common in adults. At the 
present time, the most basic sociodemographic characteristics of pediatric ME/CFS in the general po-
pulation have not been reliably identified. A variety of socio-environmental and psychological risk 
factors associated with ME/CFS onset and maintenance over time in adults (i.e., female gender, older 
age, minority status, lower socioeconomic status (SES), and higher fatigue severity [29]) need to be 
studied with a pediatric ME/CFS sample. It is also important to identify whether there are any asso-
ciations with a variety of predisposing and precipitating risk factors (e.g., exposure to mononucleosis; 
immunizations; first, second and third degree relatives’ ME/CFS and health status; psychiatric status, 
etc.) and pediatric ME/CFS in a community-based sample.
Non-pharmacologic rehabilitative interventions are used for people with cancer and heart disease, but 
they are only one component of the treatment plan, and, when used by themselves, are not curative. 
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Comprehensive approaches are also needed for 
patients with ME/CFS, and helping patients ma-
nage their illness non-pharmacologically is only 
one aspect of rehabilitation. Historically, resear-
chers have focused on the potential benefits of 
cognitive behavioral interventions. As discussed, 
the long-term outcomes of this type of interven-
tion are still unclear, but interventions that chal-
lenge basic patient illness beliefs might solidify 
already negative attitudes of medical personnel 
toward people with ME/CFS. The Energy Enve-
lope Theory represents an alternative approach 
for helping patients, as it helps patients better 
monitor energy levels, stay within their energy 
envelopes, sustain lifestyle changes that involve 
reprioritizing activities, and possibly rebalance 
their lifestyle between work and leisure.
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